Thursday 18th December, 2025 Serious concerns raised by Sri Lankan medical professionals over the quality of some batches of the Ondansetron injection, manufactured by Maan Pharmaceuticals, Ltd., ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
The FDA has released new guidance reducing the need for animal testing in monoclonal antibody cancer drugs when human-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback